Wrinkles
Conditions
Brief summary
The primary objective of this study is to compare the efficacy of intense focused ultrasound and carbon dioxide-fractionated laser for treatment of periorbital wrinkles.
Detailed description
This is a prospective randomized comparison study comparing the efficacy of micro-focused ultrasound versus fractionated carbon dioxide laser for treatment of periorbital wrinkles. Subjects who meet inclusion and exclusion criteria will be enrolled in the study. The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments.
Interventions
PROCEDURELaser treatment
The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
High-intensity focused ultrasound (HIFUS) is an FDA-approved method for periorbital treatment and nonablative tissue tightening. Ultrasound waves induce a vibration in the tissue, generating heat and increasing the tissue temperature within a focal area. The tissue changes depend on amount of heat and exposure duration. These findings are similar to the thermally induced changes within the skin after CO2 laser fractional ablative treatments.
Sponsors
Northwestern University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 35-60 years old male and female subjects with moderate lower eyelid rhytids and crowsfeet 2. Subjects with Fitzpatrick skin type I-III. 3. Subjects who are willing, have the ability to understand and provide informed consent, and are able to communicate with the investigator.
Exclusion criteria
1. Subjects who have received injectable soft-tissue augmentation materials to the face, or facial ablative resurfacing, within the past 6 months. 2. Subjects who were received injectable botulinum toxin to the face, or any nonablative laser treatment to the face, within the past 3 months. 3. Subjects who have local infections, open facial wounds, or other significant local skin disease that would interfere with periorbital treatment with energy devices. 4. Subjects who are allergic to lidocaine or prilocaine. 5. Subjects who have a history of abnormal scarring in the treatment area. 6. Subject who have ectropion or or other eyelid disfigurement. 7. Subjects who have history of isotretinoin use in the preceding year 8. Pregnant or lactating individuals
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Global Improvement Scale | 3 months | Global improvement scale score, as a percent improvement from baseline to 1 and 3 months, respectively, after treatment. Two non-treating dermatologists will independently blindly evaluate the photographs at baseline, 1 and 3 months after treatment; differences will be resolved via a forced agreement process. |
| Quantitative eyelid laxity scale | 3 months | Two non-treating dermatologists will independently blindly evaluate the photographs at baseline, 1 and 3 months after treatment; differences will be resolved via a forced agreement process. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subject Satisfaction | 10 years | Subject satisfaction will be determined by a satisfaction questionnaire, and subjects will be asked to select the treatment side they preferred |
| Adverse events | 10 years | Any adverse events related to the use of the fractionated laser and ultrasound-tightening device (e.g. infection, prolonged erythema, prolonged edema, bleeding, ulceration, erosion or pigmentation) will be recorded. |
Countries
United States
Outcome results
None listed